Literature DB >> 23805375

Management Strategies for Elderly Patients with Diffuse Large B-Cell Lymphoma.

Loretta J Nastoupil1, Rajni Sinha, Christopher R Flowers.   

Abstract

Entities:  

Year:  2012        PMID： 23805375      PMCID： PMC3690666          DOI： 10.17925/eoh.2012.08.02.123

Source DB:  PubMed          Journal:  Eur Oncol Haematol        ISSN： 2045-5275


× No keyword cloud information.
  51 in total

Review 1.  Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma.

Authors:  Lodovico Balducci; Lazzaro Repetto
Journal:  Cancer       Date:  2004-01-01       Impact factor: 6.860

2.  Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI).

Authors:  Ranjana H Advani; Haiyan Chen; Thomas M Habermann; Vicki A Morrison; Edie A Weller; Richard I Fisher; Bruce A Peterson; Randy D Gascoyne; Sandra J Horning
Journal:  Br J Haematol       Date:  2010-10       Impact factor: 6.998

3.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

Authors:  R I Fisher; E R Gaynor; S Dahlberg; M M Oken; T M Grogan; E M Mize; J H Glick; C A Coltman; T P Miller
Journal:  N Engl J Med       Date:  1993-04-08       Impact factor: 91.245

4.  Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.

Authors:  J M Vose; B K Link; M L Grossbard; M Czuczman; A Grillo-Lopez; P Gilman; A Lowe; L A Kunkel; R I Fisher
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

5.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  P Feugier; A Van Hoof; C Sebban; P Solal-Celigny; R Bouabdallah; C Fermé; B Christian; E Lepage; H Tilly; F Morschhauser; P Gaulard; G Salles; A Bosly; C Gisselbrecht; F Reyes; B Coiffier
Journal:  J Clin Oncol       Date:  2005-05-02       Impact factor: 44.544

6.  Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial.

Authors:  Ilske Oschlies; Wolfram Klapper; Martin Zimmermann; Matthias Krams; Hans-Heinrich Wacker; Birgit Burkhardt; Lana Harder; Reiner Siebert; Alfred Reiter; Reza Parwaresch
Journal:  Blood       Date:  2006-01-19       Impact factor: 22.113

7.  Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.

Authors:  Michael J Robertson; Brad S Kahl; Julie M Vose; Sven de Vos; Mary Laughlin; Patrick J Flynn; Kendrith Rowland; Jose C Cruz; Stuart L Goldberg; Luna Musib; Christelle Darstein; Nathan Enas; Jeffery L Kutok; Jon C Aster; Donna Neuberg; Kerry J Savage; Ann LaCasce; Donald Thornton; Christopher A Slapak; Margaret A Shipp
Journal:  J Clin Oncol       Date:  2007-03-26       Impact factor: 44.544

Review 8.  Diffuse aggressive lymphoma.

Authors:  Richard I Fisher; Thomas P Miller; Owen A O'Connor
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2004

9.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Marita Kloess; Rudolf Schmits; Alfred C Feller; Christian Rübe; Christian Rudolph; Marcel Reiser; Dieter K Hossfeld; Hartmut Eimermacher; Dirk Hasenclever; Norbert Schmitz; Markus Loeffler
Journal:  Blood       Date:  2004-03-11       Impact factor: 22.113

Review 10.  Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly.

Authors:  Hannah H Wong; Jun Wang
Journal:  Leuk Lymphoma       Date:  2009-03
View more
  2 in total

1.  Efficacy and tolerability of anthracycline-based therapy in elderly patients with diffuse large B-cell lymphoma.

Authors:  Christine C Davis; Jonathon B Cohen; Katherine S Shah; Don A Hutcherson; Minal J Surati; Kelly Valla; Elyse H Panjic; Caitlin E Handler; Jeffrey M Switchenko; Christopher R Flowers
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-12-31

2.  EBV Latency III-Transformed B Cells Are Inducers of Conventional and Unconventional Regulatory T Cells in a PD-L1-Dependent Manner.

Authors:  Héloïse Auclair; Catherine Ouk-Martin; Lilian Roland; Pauline Santa; Hazar Al Mohamad; Nathalie Faumont; Jean Feuillard; Chantal Jayat-Vignoles
Journal:  J Immunol       Date:  2019-08-21       Impact factor: 5.422
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.